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Abstract
Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin
(Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in
this population but rarely induce complete response (CR). Ten patients with R/R cHL after ASCT and Bv received
pembrolizumab (n = 8) or nivolumab (n = 2). Five had been previously exposed to 5-azacitidine on a phase 1 study.
Among nine evaluable patients, seven (78%) achieved CR, one partial response, and one reduction of tumor
burden. All five patients who had received 5-azacitidine prior to ICI achieved CR, while only two of four who did
not receive prior 5-azacitidine achieved CR. At a median follow-up of 9.9 months [0.5–14.3], eight patients are alive and
five are still receiving treatment. We documented an unprecedented CR rate after ICI in patients with R/R cHL. We
hypothesize that hypomethylating agents might have an immune priming effect and enhance the efficacy of ICI.
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To the editor
Patients with classical Hodgkin lymphoma (cHL) refractory
to, or relapsed after, autologous stem cell transplantation
(ASCT) and brentuximab vedotin (Bv) have limited treat-
ment options and represent an unmet medical need [1].
The immune checkpoint receptor programmed death
(PD)-1 is expressed on T cells and causes reversible an-
ergy when engaged by its ligands after antigen recogni-
tion by the T cell receptor [2]. Expression of PD-ligand
(L)1 or PD-L2 is utilized by tumors to escape immune
surveillance [3]. cHL exhibits a genetically determined
overexpression of PD-L1/PD-L2 due to recurrent ampli-
fication of 9q24.1 [4], and thus may be exquisitely sensi-
tive to PD-1 blockade. The anti-PD-1 monoclonal
antibodies nivolumab and pembrolizumab, two immune
checkpoint inhibitors (ICI), are highly active in patients
with relapsed or refractory (R/R) cHL but induced
complete response (CR) only in a minority of them [5, 6].
The hypomethylating agent (HMA) 5-azacitidine was
shown to induce expression of retroviral genes in tumor
cells and trigger a T cell-mediated response, thus poten-
tially synergizing with ICI [7]. We report our experience
with ICI in ten patients with R/R cHL, five of whom were
previously exposed to 5-azacitidine.
Eight patients received pembrolizumab (2 mg/kg every
3 weeks) and two nivolumab (3 mg/kg every 2 weeks). Re-
sponse was evaluated with fluorodeoxyglucose-positron
emission tomography/computerized tomography (PET/
CT) according to the 2014 Lugano criteria [8]. Patients
with new or persistent lesions were allowed to continue
on therapy if they had disease and/or symptom control,
without unacceptable toxicity.
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The median number of prior treatments was 11 [3–16]
and 80% of patients had received ≥7 lines of therapy. All
patients had received ASCT and Bv (Additional file 1:
Table S1). Five patients had been previously treated with
5-azacitidine in combination with romidepsin within a
phase 1 clinical trial (NCT01998035) (Additional file 2:
Table S2). Median duration of 5-azacitidine therapy was
3 months [2–16]. Three patients received it immediately
prior to ICI, the other two within 14 months of initiating
ICI (Fig. 1).
The median treatment duration was 25 weeks [2–54].
Two treatment delays lasting >1 week were due to lack
of insurance coverage and diagnosis of myelodysplastic
syndrome (MDS) (Fig. 2). There were six grade ≥3 ad-
verse events (AE): one patient had an infusion reaction,
one had thrombocytopenia and was later diagnosed with
MDS, and another developed chronic myelomonocytic
leukemia (CMML) right after treatment initiation. The
latter two patients had been exposed to radiation and al-
kylating agents and developed acute myeloid leukemia
(AML), fatal in one case. One patient with chronic kid-
ney disease developed a non-steroidal anti-inflammatory
drug-related interstitial nephritis, in resolution at the
time of pembrolizumab initiation. One patient developed
hypotension, hypoxia and bilateral pulmonary infiltrates
after the first infusion and died 2 weeks later of multi-
organ failure, despite broad-spectrum antibiotics and high-
dose steroids. This patient had pre-existent depressed left
ventricular ejection fraction (20%), recurring pericardial ef-
fusion, post-radiation fibrosis and bronchiectasis, and re-
cent pneumonia. Grade 1–2 AE are summarized in
Additional file 3: Table S3.
Nine patients were evaluable for response. Seven
(78%) achieved CR and one partial response. One patient
had a significant reduction of all tumor sites and devel-
oped a new liver lesion. All five patients who had been
exposed to 5-azacitidine containing therapy achieved a
CR, whereas only two of the four who did not receive
prior 5-azacitidine achieved CR (Fig. 2). After a median
follow-up of 9.9 months [0.5–14.3] eight patients were
alive and five were still receiving treatment after 23, 39,
48, 48, and 54 weeks. The patient with a new liver lesion
had stable disease, no new symptoms, and no significant
toxicity, thus continued to receive ICI therapy. Three pa-
tients discontinued therapy: one transitioned to alloSCT
while in CR after 9 weeks of therapy and remains in re-
mission 1 year later; one discontinued while in CR after
17 weeks, due to transformation of CMML into AML;
Fig. 1 Previous therapies and respective duration of disease control. For each patient, bar length and number represent the time to next treatment (in
months). Section sign includes salvage chemotherapy followed by high-dose chemotherapy and ASCT; Asterisk indicates Bv induction followed by ASCT
consolidation and Bv maintenance. Abbreviations: ICI immune checkpoint inhibitor, Bv brentuximab vedotin, ASCT autologous stem cell transplantation,
AlloSCT allogeneic stem cell transplantation
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and the third patient discontinued treatment due to con-
firmed progression and lack of clinical benefit after
32 weeks (Fig. 2).
To the best of our knowledge, this is the first report to
suggest clinical synergy between epigenetic therapy and
ICI in patients with cHL. In this very heavily pre-treated
cohort, ICI showed impressive clinical efficacy with a CR
rate (CRR) of nearly 80%. In phase 1 trials in patients
with R/R cHL, nivolumab (n = 23) induced an overall re-
sponse rate (ORR) and CRR of 87% and 17%, respect-
ively [5], and pembrolizumab (n = 31), at a dose of
10 mg/kg, an ORR of 65% and CRR of 16% [6]. With the
limitations of comparing separate, small series, our co-
hort appears to include more extensively pre-treated pa-
tients (Additional file 1: Table S1 and [5, 6]). Yet, most
of them achieved CR early after treatment.
All five patients previously exposed to 5-azacitidine ob-
tained PET/CT-negative CR. Recent studies suggested that
HMA can induce up-regulation of endogenous retroviral
genes in tumor cells. Endocellular sensors of viral double-
strand RNA then trigger an interferon-β-mediated T cell
response. Moreover, in a pre-clinical melanoma model, 5-
azacitidine was found to sensitize cells to ipilimumab, an-
other ICI [7]. This agent may, therefore, have a “priming”
effect on the immune system and maximize the response
to ICI. The impact of 5-azacitidine might be harder to as-
sess in patient N. 5, as he received the drug about 1 year
prior to starting ICI. Unlike 5-azacitidine, histone deacety-
lase inhibitors have not been shown to synergize with ICI.
However, because 5-azacitidine was administered in
combination with romidepsin in our patients, we cannot
exclude that additional romidepsin-mediated modulation
of gene expression might have further potentiated the ef-
fects of ICI, thus contributing to the high CRR. Other lim-
itations of our retrospective study include the small
sample size, the retrospective nature of the study, the het-
erogeneous duration and timing of HMA therapy, and the
use of different ICI. Nevertheless, the uniquely high CRR
cannot be explained by ICI therapy alone and may be in
part due to synergy with HMA. The combination of
epigenetic therapy and PD-1 blockade is being tested pro-
spectively at our institution.
Additional files
Additional file 1: Table S1. Characteristics of the patients included in
the present report and the studies from Ansell and colleagues and
Armand and colleagues. (DOCX 90 kb)
Additional file 2: Table S2. Treatment schedule of combined 5-
azacitidine and romidepsin (phase 1 study, NCT01998035). (DOCX 57 kb)
Fig. 2 Type of immune checkpoint inhibitor, treatment duration, dose intensity, and type and duration of response. For each patient, the bar length
indicates the amount of time spent in a specific (color-coded) disease state. Abbreviations: AlloSCT allogeneic stem cell transplantation, MDS
myelodysplastic syndrome, AML acute myeloid leukemia, CR complete response, ICI immune checkpoint inhibitor
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Additional file 3: Table S3. Adverse events observed during immune
checkpoint inhibitor therapy. (DOCX 15 kb)
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